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Tumors exhibit complex organization and contain a variety of cell populations. The realization that the
regenerative properties of a tumor may be largely confined to a cell subpopulation (cancer stem cell) is
driving a new era of anti-cancer research. Cancer stem cells from Glioblastoma Multiforme tumors express
markers that are also expressed in non-cancerous neural stem cells, including nestin and Sox2. We
previously showed that the transcription factor Hes3 is a marker of neural stem cells, and that its expression
is inhibited by JAK activity. Here we show that Hes3 is also expressed in cultures from glioblastoma
multiforme which express neural stem cell markers, can differentiate into neurons and glia, and can
recapitulate the tumor of origin when transplanted into immunocompromised mice. Similar to
observations in neural stem cells, JAK inhibits Hes3 expression. Hes3 RNA interference reduces the number
of cultured glioblastoma cells suggesting a novel therapeutic strategy.
G
lioblastoma Multiforme (GBM) is the most common primary brain tumor and is associated with very
poor prognosis1,2. Tumor initiating cells (Cancer Stem Cells, ‘‘CSCs’’) have been identified in GBM3–7 and
a race is on to understand how to target them as a potential therapeutic avenue. Although the lineage
connection between non-cancerous neural stem cells (NSCs) and CSCs is not established, these cell types share
several properties including signaling pathways that contribute to their growth as well as the expression of
common markers including nestin and Sox28.
We recently demonstrated that the transcription factor Hes39–11 is a marker of established neural stem cell
cultures from the fetal and adult rodent central nervous system12–16. Factors that promote the expansion of these
cells, including Notch ligands, Angiopoietin 2, insulin, as well as inhibitors of the Janus kinases (JAK) and
p38MAP kinases, also increase the expression of Hes3. In the adult rodent and primate brains, Hes3 identifies
a perivascular cell subpopulation that co-expresses other markers of immature cells, such as Sox2. In this report,
we demonstrate that HES3 not only provides a novel identifying marker for the CSC population in GBMs, but is a
key mediator of the number of these cells, thereby offering a potential therapeutic target.
Results
In biopsies from patients with GBM, Hes3 co-localizes with the putative cancer stem cell marker prominin14,17,18
(Fig. 1a,b). These results agree with the observations that magnetic immunoprecipitation of cells from the rodent
brain using an antibody against prominin generate a cell fraction which is enriched in Hes31/Sox21 cells14.
Taken together, these data suggest that Hes3 may be expressed in putative cancer stem cells in GBM and that it
may mediate cell number expansion.
To address the potential value of Hes3 as a target in cancer medicine, we used primary cultured cells that were
isolated from GBM biopsies. These cells were maintained in vitro using standard protocols for the establishment
of non-cancerous neural stem cells cultures19–21. These cells can be expanded with the support of the mitogen
Epidermal Growth Factor (EGF) or basic Fibroblast Growth Factor (bFGF)21. Our previous work has established
that the same cells used in this study can be propagated in culture over long periods of time and many passages,
express several markers of NSCs, including, Sox2 and nestin, as well as prominin, can be induced to differentiate
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into neurons, astrocytes, and oligodendrocytes, they phenocopy the
tumor of origin in xenograph experiments, and they respond to
many growth factors that NSCs also respond to21,22.
We recently showed that cultured NSCs express Angiopoietin 2
(Ang2) as well as its receptor, Tie2, and that treatment with Ang2
increases cell number both in vitro and in vivo14,15. Here we show that
GBM cells also express Ang2 together with the more established
marker Sox2 (Fig. 1c). NSCs express a small number of GM11 gang-
liosides on their cell surface which can be identified by binding to a
fluorophor-conjugated B subunit of cholera toxin16; in contrast, their
differentiated progeny expresses many binding sites. In our cultured
GBM cells (in the presence EGF or bFGF), a very small percentage of
cells labeled with conjugated cholera toxin (Fig. 1d–f). In con-
trast, when cells where treated with serum (which induces the
Figure 1 | Hes3 is expressed in putative cancer stem cells in glioblastoma. (a) Hes31 cells are located adjacent to blood vessels in biopsies from GBM
patients. (A blood vessel lumen is marked in white; green arrows point to Hes31 cells; the red arrow points to nuclei of vascular cells). (b) Another
example of Hes31 cells in a GBM tumor show co-localization of Hes3 with prominin (red and green split channels are shown side-by side). White circles
show the location of the nuclei, some of which appear positive for Hes3 signal (Marked by green arrows). (c) Cultured GBM cells co-express Sox2 and
Ang2. (d-f) GBM cells in the presence of EGF and the absence of serum (‘‘Self-Renewal’’) express low amounts of GM11 gangliosides, identified by
labeling with a fluorophore-conjugated cholera toxin B subunit; addition of serum for 4 days increases labeling. (g) Diagram showing positive regulation
on Hes3 transcription by bFGF via phosphorylation of STAT3-serine, and opposition by JAK activity. Hes3 is positively regulated by signals that promote
STAT3-serine phosphorylation in the absence of STAT3-tyrosine phosphorylation. In NSCs, such signals include bFGF, insulin, the Notch ligands Delta4
and Jagged1, and Angiopoietin 2. Signals that induce the JAK/STAT pathway (which leads to STAT3-tyrosine phosphorylation) do not induce Hes3
transcription. Such signals include CNTF, EGF, and components of serum. [Nuclei are stained with DAPI and appear blue. Size bar: 100 micrometers].
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differentiation of NSCs), the number of cholera toxin binding sites
greatly increased. These results further support that the cultured
GBM cells used express markers commonly associated with neural
stem cells and that they possess the potential to differentiate into cells
representing the main cell types of the nervous system.
Our previous work with NSCs showed that Hes3 expression is
opposed by the actions of JAK. Its activity can be assessed by mea-
suring STAT3 phosphorylation on tyrosine residue 705 (STAT3-
Tyr), which is downstream of JAK23. In contrast, Hes3 expression
is supported in conditions where STAT3 is phosphorylated on serine
residue 727 (STAT3-Ser)12. NSCs cultured in bFGF exhibit low Hes3
mRNA levels, but these can be increased by concomitant exposure to
Ciliary Neurotrophic Factor (CNTF) and JAK inhibitor (JAK I)12,
a treatment which elevates STAT3-Ser and inhibits STAT3-Tyr
(Suppl. Fig. 1a,b). Similar results can be obtained by low concentra-
tions of CNTF24 that also elevate STAT3-Ser but not STAT3-Tyr
phosphorylation (Suppl. Fig. 1c). The potential of JAK I to promote
the undifferentiated state in NSC cultures is also demonstrated by the
fact that it inhibits the expression of the glial marker GFAP in the
presence of bFGF (Suppl. Fig. 1d). Low CNTF concentrations or
concomitant high concentrations of CNTF and JAK I increase the
number of cultured NSCs in the presence of bFGF (Suppl. Fig. 1e).
We hypothesized that GBM cells cultured in the absence of serum
and the presence of mitogen would induce the expression of Hes3
and, therefore, they would resemble, in that respect, the cells of their
origin in the patient. We tested the following four conditions: (a)
EGF, (b) EGF 1 JAK I, (c) bFGF, and (d) bFGF 1 JAK I. We found
that the highest STAT3-Ser and lowest STAT3-Tyr phosphorylation
state was in the FGF 1 JAK I condition (Fig. 2a). In these conditions,
cells were able to proliferate; in fact, their number was greater than in
the other conditions, after one week of treatment (Fig. 2b). We note
that inclusion of the JAK inhibitor allowed cell cultures to reach a
higher terminal cell density, as assessed by cell number counting
following a 2 week treatment (Fig. 2c,d). Hes3 expression varied
among the four conditions; the highest incidence of Hes31 cells
was in the bFGF 1 JAK I condition (Fig. 2e,f). Since the culture
system presented here lacks serum to support cell growth, the pres-
ence of a mitogen (bFGF or EGF) is required. As a consequence, we
studied the effects of treatments (e.g. JAK I) in the presence of these
defined factors.
To address whether Hes3 is a mediator of the expansion of GBM
cells and, therefore, a putative anti-cancer target, we performed
transfections with Hes3 siRNA. We tested two different control
(‘‘scrambled’’) siRNA products and three different Hes3 siRNA pro-
ducts for corroboration. We performed the experiments in both EGF
and bFGF 1 JAK I conditions to show the sturdiness of the result and
to demonstrate that the effect of Hes3 interference is not an artifact of
a particular cell culture system. In all cases, Hes3 interference caused
the reduction of Hes3 expression, as expected, and a reduction in cell
number (Fig. 2g). We confirmed the results using two additional
GBM cell cultures established from different patients (Fig. 2h–j). A
cell survival assay showed a reduction in viability in the Hes3 siRNA
– transfected cells, suggesting that, partly, the reduction in cell num-
ber is due to a reduction in viability (Fig. 2k).
Discussion
Brain tumors contain multiple cell types, some of which may carry
the lion’s share of the regenerative properties of the tumor, mani-
fested as metastasis and recurrence. Different subpopulations of cells
express different sets of markers (with plenty of overlap) allowing for
the ability to distinguish among these cell types to a certain degree.
These cells may also differ in terms of the signal transduction path-
ways they utilize in order to grow. Given the variations in extracel-
lular signals within the tumor microenvironment, this is a logical
postulate. It is, therefore, critical to study and define different
signaling systems that contribute to the growth of tumors and design
manipulations to counteract tumor growth.
In this manuscript we applied findings that we generated during
our previous work with non-cancerous NSCs12–16. This work showed
that NSCs utilize non-canonical signal transduction pathways to
regulate their survival and numbers in vitro and in vivo. Key to these
non-canonical pathways is the phosphorylation state of STAT3.
When STAT3 is phosphorylated on serine 727 in the absence of
detectable phosphorylation on tyrosine 705, cells survive and prolif-
erate in a self-renewing manner. In contrast, when the tyrosine res-
idue is also phosphorylated, NSCs differentiate with a preference
towards glial fates19,25,26. STAT3-Ser phosphorylation promotes the
expression of the transcription factor Hes3, which we showed to be a
novel biomarker of established NSCs. In addition, Hes3 identifies
new pools of cells in various areas of the adult brain which can be
placed in culture where they exhibit self-renewal and multi-poten-
tiality, generating neurons, astrocytes, and oligodendrocytes.
We also showed that Hes3 is expressed in tumor tissue from glio-
blastoma patients, and that it co-localizes with the putative CSC
marker prominin. Here, we extended our studies to show that (1)
primary GBM cell cultures also express Hes3 under conditions that
support STAT3-Ser phosphorylation and suppress STAT3-Tyr
phosphorylation and that (2) Hes3 interference reduces the numbers
of cells in culture.
These early results suggest that Hes3 is a new marker of GBM cells
and a mediator of cell expansion. Future studies will address the
relevance of Hes3 in cultures from different GBM subtypes (e.g., as
defined by The Cancer Genome Atlas). It will also be important to
address the mechanisms that regulate the cell number changes
reported here. For example, our results help distinguish between cell
expansion rates and maximal cell density. Specifically, whereas inclu-
sion of the JAK I in the presence of EGF did not alter cell number
during the early culture phase, it did allow cells to reach higher
densities. Given that JAK is implicated in the canonical Notch sig-
naling pathway and subsequent gliogenic differentiation27, it is intri-
guing to speculate that non-canonical Notch signaling branches
which are opposed by JAK12 may be competing with canonical path-
ways and that Hes3 may be a critical regulator of the balance between
these two branches.
Our previous work with non-cancerous NSCs showed that activa-
tion of the STAT3-Ser/Hes3 signaling pathway promotes cell sur-
vival without altering the cell cycle duration12. Whether this applies
to GBM cells, will have to be determined in future studies.
It is difficult to define a cancer stem cell population. The GBM-
derived cells used in this work, however, do exhibit CSC properties,
as suggested by their (1) expression of undifferentiated markers, (2)
ability to differentiate into neuron and glia - like cells, and (3) ability
to phenocopy the tumor of origin in immunocompromised mice.
These results suggest that Hes3 may be relevant as a target for the
elusive CSC population of GBM and, possibly other solid tumors
such as breast, colon and pancreatic cancers28–32. Preliminary results
show that in spontaneously arising brain tumors in adult mouse null
for the p53 tumor suppressor gene, Hes31 cells are clearly seen both
within the tumor mass (identified by morphology and staining for
KI67), as well as outside the borders of the tumor (data not shown).
Additional work will require validation in multiple in vitro and in
vivo paradigms.
Beyond the possible value of Hes3 as a CSC target, these results
show that the same cell (or cell line) is capable of utilizing distinct
signaling pathways to ensure its growth. Glioma cells are often cul-
tured in the presence of serum, or in the absence of serum with EGF.
Here we show that the same GBM cell cultures can be cultured in
EGF or FGF 1 JAK I in the absence of serum. EGF and serum
components activate the JAK-STAT pathway which suppresses
Hes3 expression, whereas bFGF activates the STAT3-Ser pathway
which induces Hes3 expression. Therefore, the same cell can grow
www.nature.com/scientificreports
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under conditions that not only are starkly different, but even oppos-
ing. This complexity at the level of signal transduction of a single cell
confers growth options to the cell and may be a major contributor to
the difficulties in combating cancer.
Methods
Neural stem cell culture. Neural Stem Cell cultures from the mid-gestation (E13.5)
mouse embryo cortex were grown as previously described14. Tissue was dissected
under a dissection microscope, triturated in 1 ml N2 medium containing bFGF
with a 1 ml pipette until no tissue clamps were seen; the triturate was allowed to
settle for 1 min and the top 0.9 ml was collected, diluted in N2 containing bFGF
and plated. Cells were expanded in serum-free DMEM/F12 medium with N2
supplement and bFGF (20 ng/ml) for 5 days under 5% oxygen conditions and
were re-plated fresh or from frozen stocks at 1,000–10,000 cells per cm2. bFGF
was included throughout our experiments, unless otherwise stated. To induce
differentiation, the culture medium was replaced with fresh culture medium which
does not contain bFGF and the cells were incubated for 5 days. Treatments were
as described in the main text. In the experiments involving the treatment of cells
with CNTF and the JAK inhibitor, the inhibitor was added to the culture medium
30-min prior to the CNTF.
Figure 2 | Hes3 regulates the number of GBM cells in culture. (a) Culture conditions affect the phosphorylation states of STAT3 of GBM cells. (b) GBM
cells grow efficiently in the four conditions described in the text (7-d). (c) JAK inhibition increases the terminal cell density that GBM cells reach
(14-d). (d) JAK inhibition increases the terminal cell density that GBM cells reach (14-d; representative phase contrast images). (e) Culture conditions
regulate the probability that GBM cells will express Hes3 (7-d). (f) Examples of Hes3 staining in human GBM cells, in the FGF1JAK I conditions (7-d; size
bar: 25 micrometers. Nuclei are stained with DAPI and appear blue). (g) Hes3 knockdown in GBM cells (line ‘‘X08’’) reduces the amount of Hes3 protein
and cell number (5-d). Each control bar represents a different control (‘‘scrambled’’) siRNA product and each of the three ‘‘Hes3’’ labeled bars represents
a different Hes3 siRNA product for corroboration. (h–j) Similar results are obtained using two additional GBM cell cultures (‘‘X01’’ and ‘‘X04’’)
in the presence of EGF. (k) A cell viability assay (Promega MTS) shows reduced viability following Hes3 interference (5-days).
www.nature.com/scientificreports
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Glioblastoma cell culture. Three GBM cell lines (‘‘X01’’, ‘‘X04’’, and ‘‘X08‘‘ lines)
were established from acutely resected human tumor tissues (Glioblastoma
multiforme). Resected tissue was treated using the protocol described above for
mouse fetal neural stem cells. Cells were cultured under the same conditions that were
used for rodent neural stem cells. Variations in their mitogenic support are noted in
the text. Treatments were as described in the main text.
Pharmacological Treatments. bFGF and EGF were purchased from RnD Systems
and were used at a concentration of 20 ng/ml. JAK inhibitor was purchased from
Calbiochem and was used at a concentration of 200 nM.
Human biopsies of solid tissue. All human tissues in this study were obtained during
surgical resections from patients with newly diagnosed or recurrent tumors. Materials
in excess of pathological evaluation were used for research purposes in accordance
with protocols approved by the Institutional Review Board of the National Institutes
of Health. Written consent was obtained and all research tumor tissues were de-
identified.
Animal handling. Animals were handled and housed according to the German
Federal guidelines for the use and care of laboratory animals, and the study was
approved by the Landesdirektion Dresden. For research performed at the National
Institutes of Health (USA), all research involving animals was conducted in
accordance with NINDS ACUC (National Institute of Neurological Disorders and
Stroke/Animal Care and Use Committee) guidelines and after their approval.
RNA interference. We used the Amaxa nucleofector equipment to electroporate
siRNA into GBM cell cultures. Two control siRNA products were used (Santa Cruz
Biotechnology, sc37007 and OriGene Tech, SR3004) and three anti-Hes3 siRNA
products (Santa Cruz Biotechnology, sc88003and OriGene Tech, SR318208A and
SR318208C). The day before transfection, 5 million cells were dissociated from a
culture flask and transferred to T25 Falcon culture flask with suspension medium
containing EGF or bFGF. Cells were then transfected with siRNA using a
nucleofecting electroporator according to the manufacturer’s protocol (Amaxa Inc.,
Gaithersburg, MD, USA). After 24 h, the medium was replaced, and cells were
harvested for additional experiments. Typical transfection efficiency was at
approximately 80%21,22.
Reverse transcriptase PCR. RNA was extracted from cell cultures with Trizol
(Invitrogen, 15596-026), and PCR reactions were performed with the ProSTAR First-
Strand RT-PCR Kit (Stratagene, 200420).
Immunohistochemistry. Under deep anesthesia, animals were perfused
transcardially with a rinse of saline, followed by 4% formaldehyde fixative (pH 7.4).
Brains were removed immediately, stored in the fixative solution overnight, and then
in 30% sucrose for 3 days. Brains were frozen-sectioned at 16 or 30 micrometers.
Immunocytochemistry. Cells were fixed onto the culture plate by replacing the
culture medium with ice cold 4% formaldehyde fixative (pH 7.4), for 30 min. PFA
was washed twice with PBS and the cells were immunostained using standard
techniques.
Western Blot analysis. Western Blot analyses were performed using standard
protocols. Briefly, Laemmli Sample Buffer from Bio-Rad was used as the harvesting
buffer. Samples were boiled for 15 min and approximately 40 microgram of protein
was loaded per well. Primary antibodies were used at a dilution of 15500 and
secondary antibodies at 154,000. Antibodies were diluted in 5% BSA in PBST.
Primary antibodies were incubated overnight, with mild shaking, at 4 degrees Celsius.
Cell viability assays. Cell viability was measured by the MTS assay (Promega).
Reagents. We used the following reagents and antibodies: bFGF (233-FB),
fibronectin (1030-FN), from R&D; JAK Inhibitor I (420099), from Calbiochem;
Polyornithine (P-3655), insulin (I9278) from Sigma; Alexa-Fluor-conjugated
secondary antibodies from Invitrogen; DAPI (D-8417) from Sigma, ECL reagents
(34080) from Pierce, polyacrylamide gradient gels from Invitrogen, HRP-conjugated
secondary antibodies from Jackson Immunoresearch, and general chemicals from
Sigma. For immunohistochemical staining and Western Blotting, we used antibodies
against the following markers: Hes3 (25393), STAT3 (482), pSer727-STAT3 (8001-
R), pTyr705-STAT3 (7993) from Santa Cruz; a-tubulin from Sigma, (T-6074). Hes3
siRNA was from Santa Cruz Biotechnology and OriGene Tech (please see
Electroporation section).
Statistical analysis. Results shown are the mean 6 S.D. Asterisks identify
experimental groups that were significantly different (p-value,0.05) from control
groups by the Student’s t-test (Microsoft Excel), where applicable.
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